耐多药结核患者家庭接触者接受预防性治疗的意愿:国际多中心横断面研究
该研究在8国16个中心对278例MDR-TB/RR-TB指示病例的743名家庭接触者进行横断面调查,评估其接受假设性MDR-TB预防治疗的意愿。结果显示79%的接触者愿意接受,即使存在轻度副作用仍有70%愿意;就业或就学、结核知识适当、有信心服药及愿意告知他人与更高意愿相关。
要点
- MDR-TB家庭接触者接受预防治疗的意愿高达79%,轻度副作用下仍达70%。
- 就业或就学、结核知识适当、有信心及愿告知他人与更高意愿独立相关。
- 结果支持在MDR-TB接触者中实施有效预防治疗的潜在可行性。
核心结论
- MDR-TB/RR-TB指示病例的家庭接触者中,愿意接受假设性MDR-TB预防治疗的比例很高,为实施有效预防治疗时的潜在接受度提供了重要证据。
研究设计与样本
- 国际多中心横断面研究,纳入8个国家16个临床研究中心的278例MDR-TB/RR-TB指示病例家庭中的743名家庭接触者。
主要发现
- 家庭接触者接受假设性MDR-TB预防治疗的意愿为79%,即使存在轻度副作用仍为70%。
- 当前就业或就学与更高意愿相关(aOR 1.83,95%CI 1.07-3.13)。
- 适当的结核相关知识与更高意愿相关(aOR 2.22,95%CI 1.23-3.99)。
- 对服用MDR-TB预防治疗有信心与更高意愿相关(aOR 7.16,95%CI 3.33-15.42)。
- 愿意告知他人正在服用MDR-TB预防治疗与更高意愿相关(aOR 2.29,95%CI 1.29-4.06)。
临床怎么用
- 可利用与意愿相关的接触者层面因素(就业或就学、结核知识、服药信心、告知他人意愿)指导教育和咨询,以提高MDR-TB预防治疗的信心和接受度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Household contacts (HHCs) of individuals with multidrug-resistant tuberculosis (MDR-TB) are at high risk of infection and subsequent disease. There is limited evidence on the willingness of MDR-TB HHCs to take MDR-TB preventive therapy (MDR TPT) to decrease their risk of TB disease. METHODS: In this cross-sectional study of HHCs of MDR-TB and rifampicin-resistant tuberculosis (RR-TB) index cases from 16 clinical research sites in 8 countries, enrollees were interviewed to assess willingness to take a hypothetical, newly developed MDR TPT if offered. To identify factors associated with willingness to take MDR TPT, a marginal logistic model was fitted using generalized estimating equations to account for household-level clustering. RESULTS: From 278 MDR-TB/RR-TB index case households, 743 HHCs were enrolled; the median age of HHCs was 33 (interquartile range, 22-49) years, and 62% were women. HHC willingness to take hypothetical MDR TPT was high (79%) and remained high even with the potential for mild side effects (70%). Increased willingness was significantly associated with current employment or schooling (adjusted odds ratio [aOR], 1.83 [95% confidence interval {CI}, 1.07-3.13]), appropriate TB-related knowledge (aOR, 2.22 [95% CI, 1.23-3.99]), confidence in taking MDR TPT (aOR, 7.16 [95% CI, 3.33-15.42]), and being comfortable telling others about taking MDR TPT (aOR, 2.29 [95% CI, 1.29-4.06]). CONCLUSIONS: The high percentage of HHCs of MDR-TB/RR-TB index cases willing to take hypothetical MDR TPT provides important evidence for the potential uptake of effective MDR TPT when implemented. Identified HHC-level variables associated with willingness may inform education and counseling efforts to increase HHC confidence in and uptake of MDR TPT.
引用
- Suryavanshi N, Murrill M, Gupta A, et al. Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study. Clin Infect Dis. 2020. PMID: 30919881. doi:10.1093/cid/ciz254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。